Biologics Litigation On The Upswing

Law360, New York (August 1, 2008, 12:00 AM EDT) -- As more biologics come into the marketplace and as more gene patents get issued, attorneys are expecting to see a gradual increase in patent litigation from biotech companies jockeying for position.

Biologics, which are typically made from human or animal proteins, are less established than their pharmaceutical cousins. But companies such as Amgen Inc. and Genentech Inc. have been obtaining gene patents since the late 1970s and the industry has been expanding ever since.

“I think the safe money is betting that there will be a...
To view the full article, register now.